Healthcare provider profile · identity verified

Darya Sterling, D.O

Family Practice · ALPHARETTA, GA · NPI 1376958850

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	244	74
Losartan Potassium	Losartan Potassium	226	69
Atorvastatin Calcium	Atorvastatin Calcium	170	60
Rosuvastatin Calcium	Rosuvastatin Calcium	159	59
Amlodipine Besylate	Amlodipine Besylate	144	51
Metformin Hcl	Metformin Hcl	129	41
Lisinopril	Lisinopril	118	38
Sertraline Hcl	Sertraline Hcl	108	35
Metoprolol Succinate	Metoprolol Succinate	103	38
Escitalopram Oxalate	Escitalopram Oxalate	101	34
Simvastatin	Simvastatin	100	31
Azithromycin	Azithromycin	94	75
Trazodone Hcl	Trazodone Hcl	90	33
Alprazolam	Alprazolam	77	46
Pantoprazole Sodium	Pantoprazole Sodium	73	32
Gabapentin	Gabapentin	72	26
Omeprazole	Omeprazole	69	27
Albuterol Sulfate Hfa	Albuterol Sulfate	66	31
Zolpidem Tartrate	Zolpidem Tartrate	64	17
Hydrochlorothiazide	Hydrochlorothiazide	59	21
Methylprednisolone	Methylprednisolone	58	44
Furosemide	Furosemide	56	25
Synthroid	Levothyroxine Sodium	55	17
Tamsulosin Hcl	Tamsulosin Hcl	50	19
Montelukast Sodium	Montelukast Sodium	48	19
Doxycycline Hyclate	Doxycycline Hyclate	45	34
Jardiance	Empagliflozin	45	17
Eliquis	Apixaban	44	15
Meloxicam	Meloxicam	44	17
Tramadol Hcl	Tramadol Hcl	40	16
Breo Ellipta	Fluticasone/Vilanterol	38	11
Bupropion Xl	Bupropion Hcl	36	15
Mounjaro	Tirzepatide	35	suppressed
Methocarbamol	Methocarbamol	34	21
Olmesartan Medoxomil	Olmesartan Medoxomil	34	11
Trulicity	Dulaglutide	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	26
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	17
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Ipratropium Bromide	Ipratropium Bromide	26	11
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	24	22
Clopidogrel	Clopidogrel Bisulfate	24	suppressed
Fluconazole	Fluconazole	24	13
Valacyclovir	Valacyclovir Hcl	24	12
Allopurinol	Allopurinol	23	suppressed
Pregabalin	Pregabalin	22	suppressed
Atenolol	Atenolol	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	20	18
Carvedilol	Carvedilol	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Famotidine	Famotidine	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Amoxicillin	Amoxicillin	16	suppressed
Clonazepam	Clonazepam	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Ozempic	Semaglutide	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Valsartan	Valsartan	13	suppressed
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Prednisone	Prednisone	12	suppressed
Diazepam	Diazepam	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error